{"id":"ribavirin-plus-interferon-beta-1a","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"20-40","effect":"Flu-like symptoms"},{"rate":"30-50","effect":"Fatigue"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Myalgia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribavirin is a nucleoside analog that interferes with viral RNA polymerase and inhibits guanosine triphosphate synthesis, reducing viral replication. Interferon-beta-1a is a type I interferon that binds to interferon-alpha/beta receptors, activating JAK-STAT signaling and inducing expression of interferon-stimulated genes with antiviral and immunomodulatory effects. The combination provides complementary antiviral mechanisms targeting both viral replication and host immune activation.","oneSentence":"Ribavirin inhibits viral RNA synthesis while interferon-beta-1a activates innate immune responses to suppress viral replication and enhance antiviral immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:07.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatitis C virus infection (in combination regimens)"},{"name":"Multiple sclerosis (interferon-beta-1a component)"}]},"trialDetails":[{"nctId":"NCT00249860","phase":"PHASE3","title":"A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2002-09","conditions":"Hepatitis C","enrollment":257}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ribavirin plus Interferon-beta-1a","genericName":"Ribavirin plus Interferon-beta-1a","companyName":"EMD Serono","companyId":"emd-serono","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin inhibits viral RNA synthesis while interferon-beta-1a activates innate immune responses to suppress viral replication and enhance antiviral immunity. Used for Hepatitis C virus infection (in combination regimens), Multiple sclerosis (interferon-beta-1a component).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}